1. Cell Cycle/DNA Damage
  2. CDK

CDK

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Related Products (101):

Cat. No. Product Name Effect Purity
  • HY-50767
    Palbociclib Inhibitor 99.94%
    Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer.
  • HY-16297
    LY2835219 Inhibitor 99.87%
    LY2835219 a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.
  • HY-50767A
    Palbociclib hydrochloride Inhibitor 99.94%
    Palbociclib hydrochloride is a highly selective CDK4/6 inhibitor with IC50s of 11 nM and 16 nM, respectively.
  • HY-15777
    LEE011 Inhibitor 99.82%
    LEE011 is a highly specific CDK4/6 inhibitor with IC50s of 10 nM and 39 nM, respectively.
  • HY-10492
    Dinaciclib Inhibitor 99.10%
    Dinaciclib is a potent inhibitor of CDK, with IC50s of 1, 1, 3, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
  • HY-13914
    Roniciclib Inhibitor
    Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
  • HY-112842
    MBQ-167 Inhibitor 99.26%
    MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
  • HY-112822
    ON-013100 Inhibitor
    ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.
  • HY-80013
    THZ1 Inhibitor 98.82%
    THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM.
  • HY-30237
    Roscovitine Inhibitor 99.77%
    Roscovitine is a potent and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
  • HY-12529
    Ro-3306 Inhibitor
    Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
  • HY-A0065
    Palbociclib isethionate Inhibitor 99.99%
    Palbociclib isethionate is a highly selective inhibitor of?CDK4/6?with?IC50s?of 11 nM/16 nM, respectively.?
  • HY-10005
    Flavopiridol Inhibitor 99.70%
    Flavopiridol is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
  • HY-80013A
    THZ1 Hydrochloride Inhibitor 98.70%
    THZ1 Hydrochloride is a selective and potent CDK7 inhibitor with an IC50 of 3.2 nM.
  • HY-103618
    THZ531 Inhibitor 99.86%
    THZ531 is a covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively.
  • HY-12214A
    NVP-2 Inhibitor 99.29%
    NVP-2 is a CDK9 inhibitor with an IC50 of 0.5 nM.
  • HY-12871
    BAY-1143572 Racemate Inhibitor >98.0%
    BAY-1143572 Racemate is the racemate mixture of BAY-1143572. BAY-1143572 is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
  • HY-101212
    CYC065 Inhibitor 98.58%
    CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK 9 kinases.
  • HY-10012
    AZD-5438 Inhibitor 99.84%
    AZD-5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It also inhibits GSK3β, but is less potent to CDK5/6.
  • HY-12302
    Kenpaullone Inhibitor 98.07%
    Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.